MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Prakash et al. conducted a scoping review and modified Delphi consensus study to map and harmonize definitions of digital health-related terms for use in health technology assessment.

At the end of March, the entity managing the DRG system in Switzerland, SwissDRG, established several unscheduled add-on reimbursement categories (ZE) for the treatment of burns with skin substitutes (autogeneic, allogeneic, alloplastic, xenogeneic). These ZE categories are valid from January 1, 2026, until December 31, 2026, for use in specific Swiss burn centers.

On April 16, 2026, the French Ministry of Health announced the inclusion of the first in vitro diagnostic medical device under the reformed RIHN 2.0, designed to support innovative diagnostics through temporary reimbursement while evidence is generated. The selected technology is VisioCyt Bladder, an AI-assisted digital urine cytology, indicated for monitoring recurrence in non-muscle-invasive bladder cancer. This marks a key milestone in the implementation of the updated framework.

On April 8, 2026, NHS England published the 2026/27 National Genomic Test Directory. The key update concerns hematological and neurological cancers, for which separate files were published with a significant restructure: new genomic test (GT) codes were introduced, gathered into new clinically relevant test packages (TP), and mapped to existing M-codes. Furthermore, multiple changes were made in the rare and inherited diseases directory, including the addition of several new codes.

In April 2026, five health apps were added to Level 3+ of the mHealthBelgium validation pyramid, making them eligible for regular reimbursement within the “Remote monitoring of oncology patients” care pathway in Belgium.

In March 2026, the National Institute for Health and Care Research (NIHR) in England released five Med Tech-related assessments in its HTA Journal, which concerned eye screening programs in diabetes, surgical and non-surgical splint treatment for finger fractures, diagnostic strategies for ovarian cancer, biomarkers for outcomes prediction in adults with suspected sepsis, and diagnostic tools of peripheral arterial disease in diabetes.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of April 20th, we plan to work on 17 projects. Review the complete list of planned activities in this post.

In April 2026, the HTA body of Tuscany Regional Healthcare released six rapid HTA reports (four new assessments and two reassessments) on medical devices in the cardiovascular, neurovascular, and dermatology fields.

On March 27, 2026, the Federal Ministry of Labor, Social Affairs, Health, Care, and Consumer Protection (BMASGPK) announced the signing of the regulation enabling the launch of the Health Reform Fund. By 2030, the Fund is expected to allocate between €497.5 million and €580 million annually, totaling more than €2.6 billion in investments to support the continued development of the healthcare system over the next five years.

In April 2026, the Danish Health Data Authority opened the application period for changes to the 2028 DRG logic, including the creation of new DRG codes and modifications to the grouping logic for existing DRGs. The application deadline is October 30, 2026.

In April 2026, five health apps were added to Level 3+ of the mHealthBelgium validation pyramid, making them eligible for regular reimbursement within the “Remote monitoring of oncology patients” care pathway in Belgium.

On April 1, 2026, the submission period for Joint Scientific Consultations (JSCs) requests under the EU Health Technology Assessment Regulation (HTAR) framework opened. JSCs offer health technology developers the opportunity to seek scientific advice on the information and evidence required for a potential future Joint Clinical Assessment. Requests related to both medical devices and medicines can be submitted until April 29, 2026.